As per MRFR analysis, the South Koreah ERG screening Market Size was estimated at 20 (USD Million) in 2023. The South KoreahERG screening Market Industry is expected to grow from 22.4(USD Million) in 2024 to 83.6 (USD Million) by 2035. The South KoreahERG screening Market CAGR (growth rate) is expected to be around 12.719% during the forecast period (2025 - 2035).
The South Korea hERG Screening Market is characterized by a variety of trends that are indicative of the changing landscape of drug development and regulatory requirements. As the South Korean government enhances its regulatory framework to guarantee drug safety, there is a substantial trend toward regulatory compliance and safety. The demand for hERG screening technologies has been driven by the Ministry of Food and Drug Safety (MFDS)'s enhancement of guidelines regarding the assessment of the cardiac safety of drug candidates.Â
Consequently, pharmaceutical companies are increasing their investments in advanced technologies that can generate precise data regarding the inhibition of hERG channels. In addition, the hERG screening landscape is being transformed by the increasing emphasis on personalized medicine. South Korean researchers are investigating genetic profiling tools that can assist in predicting a patient's response to medications, thereby reducing the risk of cardiac complications.Â
The industry has the potential to enhance the safety and efficacy of treatments by more effectively customizing them to individual patients through the integration of pharmacogenomics into hERG screening. South Korea's biopharmaceutical sector is robust and offers substantial opportunities for companies that specialize in hERG screening technologies. The hERG screening Market is poised for growth as a result of the nation's dedication to innovation and research, which is exemplified by the increased government funding for biotech initiatives.
There is potential to create sophisticated screening tools that incorporate automation and high-throughput screening methods as companies strive to optimize drug development processes while maintaining rigorous safety standards. Additionally, recent developments underscore the importance of collaboration between academic institutions and industry actors in order to improve the hERG screening process. South Korea is establishing partnerships to capitalize on its research capabilities, thereby generating synergies that could result in enhanced screening methodologies and technological advancements. This collaborative environment is essential for addressing the increasing demand for precise and efficient safety assessments in the drug development process.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
Increasing Cardiovascular Diseases
The prevalence of cardiovascular diseases in South Korea is on the rise, which is a significant driver for the South Korea hERG screening Market. According to the Korean Health Insurance Review and Assessment Service, cardiovascular diseases accounted for approximately 30 percent of total mortality rates in South Korea in recent years. The government has been actively promoting health awareness campaigns addressing heart health. This is expected to enhance the demand for hERG screening tools to help pharmaceutical companies and researchers evaluate drug-related QT prolongation risks.
This aligns with the increased focus on cardiovascular health and the need for better screening technologies by leading organizations such as the Korean Circulation Society, which advocates for advancements in cardiovascular health management. As pharmaceutical companies look to mitigate risks associated with cardiovascular drug candidates, they will expand their investments in hERG screening technologies, boosting the overall market.
Rise in Drug Development Activities
The South Korean pharmaceutical industry is actively engaged in drug development, driving the demand for hERG screening solutions. South Korea has become a hub for research and development (R&D) activities due to its robust clinical trial framework and regulatory environment. In 2021, official statistics indicated over 70 new molecular entities were under development, according to the Ministry of Food and Drug Safety. This increase in drug development necessitates a focus on safety assessments, particularly regarding cardiac effects.
Major pharmaceutical companies, including Samsung Biologics and LG Chem, are integrating hERG screening into their R&D protocols to ensure compliance with international safety standards, thereby fueling the growth of the South Korea hERG screening Market Industry. With the rising number of drug trials and a focus on cardiac safety, the demand for hERG screening technologies is anticipated to continue its upward trajectory.
Supportive Government Initiatives
The South Korean government has taken significant steps to foster growth in the biotechnology and pharmaceutical sectors, which play a crucial role in the South Korea hERG screening Market Industry. Initiatives such as the 'K-Biohealth Strategy 2020' aim to enhance the country's standing in global biotechnology markets by investing $1.6 billion in R&D and promoting collaboration between industries and academic institutions. This investment is likely to generate a favorable environment for hERG screening technologies as manufacturers seek innovative solutions to comply with rigorous safety regulations.
Organizations like the Korea Health Industry Development Institute have noted an increase in partnerships between biotech firms and academic institutions focused on cardiac safety assessments, reinforcing the demand for hERG screening solutions. As the government intensifies its investment in biotechnological advancements, the market for hERG screening is poised for remarkable growth.
The South Korea hERG screening Market showcases a growing focus on the Type segmentation, particularly with regard to Gene KCNH2 and Mutant KCNH2, both of which are crucial in assessing cardiac safety during drug development. The Gene KCNH2 plays a key role in encoding the potassium ion channel responsible for the cardiac repolarization process, and researchers continue to emphasize its importance in predicting drug-induced arrhythmias. The prevalence of congenital long QT syndrome due to mutations in the KCNH2 gene in South Korea highlights the necessity of thorough screening.
On the other hand, Mutant KCNH2, which addresses various genetic alterations affecting the ion channel function, has emerged as a focal point in the context of personalized medicine. The demand for targeted therapies necessitates robust screening techniques that can accurately identify and characterize these mutations. As South Korea aims to enhance its position in the global pharmaceutical landscape, advancements in hERG screening technologies pertaining to these specific types can drive significant improvements in drug safety profiles.Â
Furthermore, the increasing awareness of the genetic underpinnings of cardiac conditions within medical communities is fostering more in-depth investigations into the implications of KCNH2 variants, indicating a trend toward integrating genetic insights into comprehensive hERG screening methods.Overall, the significance of Gene KCNH2 and Mutant KCNH2 in the South Korea hERG screening Market underscores their essential role in advancing both safety and efficacy in therapeutic drug development.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The South Korea hERG screening Market, particularly the Ion Channel segment, plays a critical role in drug development, especially in assessing cardiac safety profiles. Voltage-gated ion channels are essential in regulating electrical impulses across membranes and are significant for understanding arrhythmias and other cardiac conditions. These channels dominate the landscape due to their direct association with numerous cardiovascular diseases, making them a key focus for pharmaceutical research. On the other hand, ligand-gated ion channels also contribute significantly to the market, acting as crucial mediators in neurotransmission and other physiological processes.
The rising emphasis on precision medicine and tailored therapies enhances the importance of these channels in screening and therapeutic applications. The South Korean government supports advancements in biotechnology, which fuels innovation within the hERG screening Market, positioning it for sustained growth. As research and development initiatives continue to evolve in the region, the demand for comprehensive hERG screening solutions tied to Ion Channel dynamics is likely to increase.
The South Korea hERG screening Market is poised to experience significant growth driven by the increasing demand for safer therapeutic agents. Within the Application domain, the landscape is characterized by diverse areas, including Antiarrhythmic, Antipsychotic, and Antibiotics, each playing a crucial role in enhancing drug safety profiles. The Antiarrhythmic segment is particularly significant as it focuses on drugs that manage irregular heartbeats, thereby requiring rigorous hERG assessments to mitigate potential cardiac risks. The Antipsychotic application area is also noteworthy due to the critical need to evaluate the effects of these medications on cardiac repolarization, impacting patient safety and therapeutic efficacy.
Antibiotics, traditionally associated with infections, are now under scrutiny to prevent adverse cardiac effects, highlighting a growing trend toward comprehensive drug evaluations. The 'Others' category captures additional applications that are shaping market dynamics. As South Korea emphasizes pharmaceutical innovation and regulatory compliance, investing in hERG screening emerges as essential for reducing risks associated with drug development and improving overall patient safety. This robust focus on rigorous safety assessment reflects the evolving priorities within the South Korea hERG screening Market industry.
South KoreahERG screening Market Key Players and Competitive Insights:
The South Korea hERG Screening Market demonstrates a dynamic and evolving landscape characterized by a strong emphasis on pharmacological safety assessments. This market is propelled by the increasing awareness of drug-related cardiac risks, leading to regulatory mandates for hERG (Human Ether-a-go-go-Related Gene) channel screening. With a growing number of pharmaceutical entities and research institutions focusing on drug development, the demand for hERG screening services has surged, positioning the market as a pivotal sector within the broader biopharmaceutical landscape.Â
Companies are actively engaging in competitive practices to enhance their service offerings, including the utilization of advanced technologies and methodologies that improve screening accuracy and efficiency. The local market also benefits from collaborations and partnerships among key players, as they seek to refine their capabilities to meet both domestic and international standards in drug safety.Medytox stands as a prominent player within the South Korea hERG screening Market, recognized for its robust approach to cardiac safety profiling in drug candidates. The company holds a considerable market presence, distinguished by its expertise in biopharmaceutical development.Â
Medytox focuses on providing high-quality hERG screening services and leverages its advanced technology to ensure thorough assessments that are compliant with international regulatory requirements. Its strengths lie in a well-established reputation for innovation and quality, which have positively influenced client trust and satisfaction. The company has fostered a collaborative environment that encourages research and development, enabling them to advance their offerings in hERG screening while maintaining their competitive edge in the South Korean market.
Pharmaton is another influential entity in the South Korea hERG screening Market, widely recognized for its commitment to enhancing drug safety through comprehensive screening solutions. The company offers a range of products and services designed to assess cardiac safety risks associated with pharmaceutical compounds. Pharmaton has built a strong market presence by aligning with local research priorities and regulatory guidelines, ensuring effective support for its clients in the drug development process.Â
The company is characterized by its continuous investment in research and development, which drives innovation in its service offerings. Furthermore, Pharmaton has engaged in strategic partnerships and mergers that bolster its market position, allowing for enhanced capabilities and access to broader expertise in hERG channel screening. Through these efforts, Pharmaton consistently addresses the evolving demands of the South Korean market, reinforcing its commitment to drug safety and compliance.
Key Companies in the South KoreahERG screening Market Include:
South KoreahERG screening Market Industry Developments
The South Korea hERG screening Market has seen significant activity recently. In August 2023, Medytox announced advancements in their hERG channel screening capabilities, enhancing drug safety evaluations, aligning with international standards. Additionally, in September 2023, Samsung Biologics collaborated with Yuhan Corporation for joint Research and Development initiatives focusing on hERG assays to expedite the drug discovery process, which has been a part of a larger shift towards innovative screening methods in the country. Moreover, in October 2023, Celltrion and Hanmi Pharmaceutical partnered to leverage their combined expertise in drug development and hERG screening, aiming to improve patient safety outcomes.Â
Furthermore, growth in market valuation continues with Korean Cancer Society reporting that the overall funding towards hERG screening technologies has increased by 20% since 2021, positively impacting companies like LG Chem and SK Biopharmaceuticals, which are now looking to invest further in the development of advanced screening techniques. In the last two years, notable investments by Daewoong Pharmaceutical in HERG-related technologies have also driven the market's evolution, underlining its increasing importance within the pharmaceutical landscape of South Korea.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 20.0(USD Million) |
| MARKET SIZE 2024 | 22.4(USD Million) |
| MARKET SIZE 2035 | 83.6(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 12.719% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Medytox, Pharmaton, Sungy Pharmaceutical, Samsung Biologics, Korean Cancer Society, Celltrion, Yuhan Corporation, CG Lifesciences, Korea Electric Power Corporation, Genexine, SK Biopharmaceuticals, LG Chem, Hanmi Pharmaceutical, Daewoong Pharmaceutical |
| SEGMENTS COVERED | Type, Ion Channel, Application |
| KEY MARKET OPPORTUNITIES | Increased regulatory pressure, Growing pharmaceutical R&D, Advancements in screening technologies, Expansion of CRO services, Rising awareness of cardiac safety. |
| KEY MARKET DYNAMICS | increasing regulatory pressures, rising drug development costs, technological advancements in screening, growing cardiovascular disease prevalence, enhanced research funding initiatives |
| COUNTRIES COVERED | South Korea |
Frequently Asked Questions (FAQ) :
The South Korea HERG Screening Market is expected to be valued at 22.4 million USD in 2024.
By 2035, the South Korea HERG Screening Market is projected to reach a value of 83.6 million USD.
The expected CAGR for the South Korea HERG Screening Market from 2025 to 2035 is 12.719%.
The Gene KCNH2 segment of the South Korea HERG Screening Market is valued at 10.5 million USD in 2024.
By 2035, the Gene KCNH2 segment is expected to grow to 39.4 million USD.
The Mutant KCNH2 segment of the market is valued at 11.9 million USD in 2024.
The Mutant KCNH2 segment is projected to reach a value of 44.2 million USD by 2035.
Key players in the market include Medytox, Samsung Biologics, and SK Biopharmaceuticals among others.
Growing research initiatives and advancements in biotechnology are primary growth drivers for the market.
Challenges include high regulatory hurdles and the need for advanced technological integration.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
